Glucotrack Inc (GCTK) Stock Price, Quote & News

Company Profile

GlucoTrack, Inc., a medical device company, focuses on the development of an implantable continuous blood glucose monitor (CBGM) for people with diabetes in the United States. The company develops the GlucoTrack CBGM, a long-term implantable blood-based CBGM for use by Type 1 diabetes patients and insulin-dependent Type 2 diabetes patients. The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc. in November 2021. GlucoTrack, Inc. was founded in 200...

Industry: Medical Devices

Sector: Healthcare

Phone: 201 842 7715

Website: glucotrack.com

Address:

301 Route 17 North, Suite 800, Rutherford, United States

RetiredOldGeezer Sep. 22 at 8:14 PM

$GCTK Taken again - that was slick.

1 · Reply

HMIC Sep. 22 at 8:13 PM

$GCTK Look for a Freaky Friday run.

0 · Reply

Tradr1205 Sep. 22 at 8:10 PM

$GCTK LESSSSGOOO!!!

0 · Reply

MrTicker Sep. 22 at 8:03 PM

$GCTK 720k float.. could be an interesting after hours to see where this closes

1 · Reply

MrTicker Sep. 22 at 8:02 PM

$GCTK on the move after hours.. + break on tap_

1 · Reply

RetiredOldGeezer Sep. 22 at 4:57 PM

$GCTK On my goodness - the hippie Hawaiians - where is your Lokahi - just a money grabber?

0 · Reply

OG80 Sep. 21 at 2:10 PM

$GCTK criminal

0 · Reply

focafoca99 Sep. 18 at 9:29 PM

$GCTK announced director Paul V. Goode's resignation over a potential conflict tied to its merger with Lokahi Therapeutics.

0 · Reply

pennysqueezepro Sep. 18 at 6:07 PM

$GCTK 👀

0 · Reply

OG80 Sep. 17 at 11:09 AM

$GCTK wheres the lawsuits?

0 · Reply

GlucoTrack Registration statement: Registration filing

2026-09-18T10:05:07.000Z - 4 days ago

GlucoTrack files to sell 43.45M shares of common stock for holders

Sep 11, 2026, 12:00 PM EDT - 11 days ago

GlucoTrack Transcript: AGM 2026

2026-09-11T12:05:08.000Z - 11 days ago

GlucoTrack announces $11.5M financing

Sep 11, 2026, 8:00 AM EDT - 11 days ago

Glucotrack Announces $11.5 Million Financing

2026-09-02T13:20:38.000Z - 20 days ago

GlucoTrack announces collaboration with SDSU Fowler College of Business

2026-08-28T23:55:29.000Z - 25 days ago

GlucoTrack Inc trading halted, news pending

2026-08-27T12:06:14.000Z - 26 days ago

GlucoTrack announces 1-for-15 reverse stock split

Aug 27, 2026, 8:00 AM EDT - 26 days ago

Glucotrack, Inc. Announces Reverse Stock Split

2026-08-25T12:15:16.000Z - 4 weeks ago

GlucoTrack subsidiary initiates clinical trial manufacturing for LT-100

2026-08-21T12:05:14.000Z - 4 weeks ago

Lokahi expands ai2 Future Labs asset origination netowrk

Aug 21, 2026, 8:00 AM EDT - 4 weeks ago

GlucoTrack Proxy statement: Proxy filing

Aug 18, 2026, 12:00 PM EDT - 5 weeks ago

GlucoTrack Transcript: AGM 2026

2026-08-17T12:11:08.000Z - 5 weeks ago

GlucoTrack achieves key compliance milestone

Aug 17, 2026, 8:00 AM EDT - 5 weeks ago

Glucotrack Achieves Key Compliance Milestone and Advances Strategic Transformation

Aug 14, 2026, 7:00 AM EDT - 5 weeks ago

GlucoTrack Quarterly report: Q2 2026

Aug 10, 2026, 8:00 AM EDT - 6 weeks ago

GlucoTrack Proxy statement: Proxy filing

Aug 6, 2026, 8:15 AM EDT - 6 weeks ago

E.F. Hutton & Co. Acts as Exclusive Financial Advisor for $5.5 Million Financing for Glucotrack

2026-08-05T14:14:16.000Z - 6 weeks ago

GlucoTrack announces $5.5M financing

Aug 5, 2026, 8:30 AM EDT - 6 weeks ago

Glucotrack Announces $5.5 Million Financing

2026-07-31T12:16:28.000Z - 7 weeks ago

GlucoTrack announces expansion of ai Futures Lab

Jul 31, 2026, 8:00 AM EDT - 7 weeks ago

Lōkahi Therapeutics™ ai² Futures Lab™ Changes How Biopharma Builds a Pipeline

Jul 31, 2026, 8:00 AM EDT - 7 weeks ago

GlucoTrack Proxy statement: Proxy filing

Jul 29, 2026, 5:30 PM EDT - 7 weeks ago

Lōkahi Therapeutics™ Advances LT-100 Development Strategy Toward Single-Injection Administration

Jul 17, 2026, 1:20 PM EDT - 2 months ago

E.F. Hutton & Co. Serves as Exclusive Financial Advisor on Strategic Business Combination Between Glucotrack and Lōkahi Therapeutics and Exclusive Placement Agent for Approximately $5.7 Million Convertible Note Financing

Jul 17, 2026, 8:05 AM EDT - 2 months ago

Glucotrack, Inc. and Lōkahi Therapeutics™ Announce Strategic Financing Support from E.F. Hutton & Co. in Connection with Their Recently Completed Business Combination and Future Capital Markets Initiatives

Jul 17, 2026, 8:00 AM EDT - 2 months ago

GlucoTrack Proxy statement: Proxy filing

Jul 16, 2026, 4:57 PM EDT - 2 months ago

UPDATE – Glucotrack and Lōkahi Therapeutics Complete Strategic Business Combination, Establishing Lōkahi-Controlled Public Platform

Jul 14, 2026, 5:40 PM EDT - 2 months ago

Glucotrack and Lōkahi Therapeutics Complete Strategic Business Combination, Establishing Lōkahi-Controlled Public Platform

2026-07-08T12:16:14.000Z - 2 months ago

GlucoTrack announces USPTO notice of allowance for patent application

Jul 8, 2026, 8:00 AM EDT - 2 months ago

Glucotrack Announces USPTO Notice of Allowance for Patent Application Covering Its Implantable CBGM Platform

Jun 17, 2026, 8:00 AM EDT - 3 months ago

GlucoTrack Proxy statement: Proxy filing

May 26, 2026, 8:00 AM EDT - 3 months ago

Glucotrack to Highlight Implantable Continuous Blood Glucose Monitoring Technology at the American Diabetes Association's 2026 Scientific Sessions

May 14, 2026, 5:27 PM EDT - 4 months ago

Glucotrack Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

May 14, 2026, 7:00 AM EDT - 4 months ago

GlucoTrack Quarterly report: Q1 2026

May 14, 2026, 7:00 AM EDT - 4 months ago

GlucoTrack Earnings release: Q1 2026

2026-05-07T17:06:12.000Z - 4 months ago

GlucoTrack submits IDE application to initiate study for CBGM technology

May 7, 2026, 1:00 PM EDT - 4 months ago

Glucotrack Announces IDE Submission for U.S. Clinical Study of its Novel Implantable Continuous Blood Glucose Monitoring Technology

May 5, 2026, 7:00 AM EDT - 4 months ago

GlucoTrack Slides: Investor presentation

Apr 30, 2026, 9:00 AM EDT - 4 months ago

Glucotrack Announces Publication of Peer-Reviewed Study In The Journal of Diabetes Research Demonstrating Long-Term Accuracy and Stability of Continuous Blood Glucose Monitoring Technology

2026-04-21T13:32:23.000Z - 5 months ago

GlucoTrack announces publication of peer-reviewed article on glucose sensors

Apr 21, 2026, 8:00 AM EDT - 5 months ago

Glucotrack Announces Publication of Peer-Reviewed Study Supporting Long-Life Sensor Design for Implantable Continuous Blood Glucose Monitoring Technology

Mar 30, 2026, 4:50 PM EDT - 5 months ago

Glucotrack Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights

Mar 30, 2026, 7:00 AM EDT - 5 months ago

GlucoTrack Earnings release: Q4 2025

Mar 30, 2026, 7:00 AM EDT - 5 months ago

GlucoTrack Annual report: Q4 2025

2026-03-27T13:29:54.000Z - 5 months ago

Why is Glucotrack Stock (GCTK) Up Nearly 30% Today?

2026-03-27T12:34:29.000Z - 5 months ago

GlucoTrack to file IDE to FDA for continuous blood glucose monitoring technology

Mar 27, 2026, 8:01 AM EDT - 5 months ago

Glucotrack to File Significant IDE with FDA for US Clinical Trial in Early Q2 Based on Critical 2025 Milestones

Mar 12, 2026, 11:00 AM EDT - 6 months ago

GlucoTrack Transcript: EGM 2026

Mar 10, 2026, 8:01 AM EDT - 6 months ago

Glucotrack to Present at LSI USA '26 Medtech Innovation Summit

Feb 9, 2026, 7:00 AM EST - 7 months ago

GlucoTrack Proxy statement: Proxy Filing

2026-01-29T13:10:24.000Z - 7 months ago

GlucoTrack announces USPTO approval for issuance of patents for CBGM platform

Jan 29, 2026, 8:01 AM EST - 7 months ago

Glucotrack Announces USPTO Approval for Issuance of Patents for Proprietary CBGM Platform

Jan 29, 2026, 7:00 AM EST - 7 months ago

GlucoTrack Proxy statement: Proxy Filing

2026-01-13T21:10:53.000Z - 8 months ago

GlucoTrack files to sell 3.22M shares of common stock for holders

Jan 13, 2026, 7:00 AM EST - 8 months ago

GlucoTrack Registration statement: Registration Filing

Dec 30, 2025, 8:00 AM EST - 8 months ago

Glucotrack, Inc. Announces Pricing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules with a Single Institutional Investor

Nov 13, 2025, 4:05 PM EST - 10 months ago

Glucotrack Reports Third Quarter 2025 Financial Results and Provides Update on Recent Corporate Highlights

Nov 13, 2025, 7:00 AM EST - 10 months ago

GlucoTrack Earnings release: Q3 2025

Nov 13, 2025, 7:00 AM EST - 10 months ago

GlucoTrack Quarterly report: Q3 2025

Nov 7, 2025, 12:00 PM EST - 10 months ago

GlucoTrack Transcript: AGM 2025

Nov 7, 2025, 7:00 AM EST - 10 months ago

GlucoTrack Proxy statement: Proxy Filing

Nov 3, 2025, 4:05 PM EST - 10 months ago

Glucotrack, Inc. Encourages Shareholders to Vote

Nov 3, 2025, 7:00 AM EST - 10 months ago

GlucoTrack Proxy statement: Proxy Filing

Oct 31, 2025, 8:00 AM EDT - 10 months ago

GlucoTrack Proxy statement: Proxy Filing

Oct 29, 2025, 4:05 PM EDT - 10 months ago

Glucotrack Appoints Neuromodulation and Painful Diabetic Neuropathy Expert, Usman Latif, MD, MBA, to Clinical Advisory Team

Oct 28, 2025, 8:00 AM EDT - 10 months ago

Glucotrack, Inc. Reminds Shareholders to Vote

Oct 28, 2025, 8:00 AM EDT - 10 months ago

GlucoTrack Proxy statement: Proxy Filing

Oct 15, 2025, 8:00 AM EDT - 11 months ago

GlucoTrack Proxy statement: Proxy Filing

Oct 8, 2025, 8:00 AM EDT - 11 months ago

GlucoTrack Registration statement: Registration Filing

Oct 3, 2025, 8:00 AM EDT - 11 months ago

GlucoTrack Proxy statement: Proxy Filing

Sep 29, 2025, 8:00 AM EDT - 11 months ago

GlucoTrack Registration statement: Registration Filing

Sep 23, 2025, 8:00 AM EDT - 12 months ago

GlucoTrack Proxy statement: Proxy Filing

Sep 16, 2025, 1:30 PM EDT - 1 year ago

GlucoTrack Transcript: Q3 Investor Summit Group Virtual Conference 2025

Sep 11, 2025, 8:00 AM EDT - 1 year ago

Glucotrack to Participate in the Q3 Virtual Investor Summit

Aug 14, 2025, 4:05 PM EDT - 1 year ago

Glucotrack Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

Aug 14, 2025, 7:00 AM EDT - 1 year ago

GlucoTrack Earnings release: Q2 2025

Aug 14, 2025, 7:00 AM EDT - 1 year ago

GlucoTrack Quarterly report: Q2 2025

Aug 6, 2025, 8:30 AM EDT - 1 year ago

Glucotrack Expands Clinical Advisory Team Appointing David S. Hirsh, MD as Medical Director, Cardiology

Jul 31, 2025, 8:30 AM EDT - 1 year ago

Glucotrack to Exhibit at 2025 Association of Diabetes Care and Education Specialists Annual Meeting

Jul 8, 2025, 8:30 AM EDT - 1 year ago

Glucotrack Announces Repurchase of Series A Warrants

Jun 25, 2025, 8:30 AM EDT - 1 year ago

Glucotrack and OneTwo Analytics Present Positive Final Results of First-In-Human Study for Continuous Blood Glucose Monitor at American Diabetes Association's 85th Scientific Sessions

Jun 12, 2025, 9:05 AM EDT - 1 year ago

Glucotrack Announces Reverse Stock Split Shareholder Approved Action Meets NASDAQ Panel Hearing Listing Requirements

Jun 4, 2025, 8:30 AM EDT - 1 year ago

Glucotrack to Showcase Long-Term Continuous Blood Glucose Monitor at American Diabetes Association's 85th Scientific Sessions

May 28, 2025, 8:30 AM EDT - 1 year ago

Glucotrack Strengthens Board of Directors with Election of Victoria E. Carr-Brendel, PhD

May 20, 2025, 8:30 AM EDT - 1 year ago

Glucotrack Establishes Patient Advisory Board to Inform Diabetes Technology Development

May 14, 2025, 5:10 PM EDT - 1 year ago

Glucotrack Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

May 14, 2025, 4:00 PM EDT - 1 year ago

GlucoTrack Quarterly report: Q1 2025

May 14, 2025, 4:00 PM EDT - 1 year ago

GlucoTrack Earnings release: Q1 2025

May 13, 2025, 8:01 AM EDT - 1 year ago

Glucotrack Announces Ethical Approval for Long-Term Clinical Study of Continuous Blood Glucose Monitor

Apr 28, 2025, 8:00 AM EDT - 1 year ago

GlucoTrack Proxy statement: Proxy Filing

Apr 18, 2025, 8:00 AM EDT - 1 year ago

GlucoTrack Proxy statement: Proxy Filing

Apr 16, 2025, 8:00 AM EDT - 1 year ago

Glucotrack to Participate in FORGETDIABETES, a Prominent European Research Initiative to Develop a Bionic Pancreas

Apr 3, 2025, 8:01 AM EDT - 1 year ago

Glucotrack and OneTwo Analytics to Collaborate for Clinical Study Analysis on Its Continuous Blood Glucose Monitor

Mar 31, 2025, 5:00 PM EDT - 1 year ago

Glucotrack Reports Full Year 2024 Financial Results and Recent Corporate Highlights

Mar 31, 2025, 5:00 PM EDT - 1 year ago

GlucoTrack Annual report: Q4 2024

Mar 31, 2025, 5:00 PM EDT - 1 year ago

GlucoTrack Earnings release: Q4 2024

Mar 19, 2025, 8:01 AM EDT - 1 year ago

Glucotrack to Present First-In-Human Study Results for Continuous Blood Glucose Monitor at the 2025 International Conference on Advanced Technologies & Treatment for Diabetes

Feb 26, 2025, 8:01 AM EST - 1 year ago

Glucotrack Appoints Guillermo Umpierrez, MD, CDCES, FACE, MACP as New Medical Advisory Board Member

Feb 4, 2025, 12:24 PM EST - 1 year ago

Glucotrack, Inc. Announces Pricing of $3.0 Million Public Offering

Feb 4, 2025, 8:01 AM EST - 1 year ago

Glucotrack Announces Successful Completion of Its First Human Clinical Study of Continuous Blood Glucose Monitor

Jan 29, 2025, 9:00 AM EST - 1 year ago

Glucotrack Strengthens Leadership Team with Appointment of New Chief Financial Officer

Jan 21, 2025, 8:01 AM EST - 1 year ago

Glucotrack Announces ISO 13485:2016 Certification

Jan 15, 2025, 8:01 AM EST - 1 year ago

Glucotrack Strenghtens Leadership Team with Addition of Industry Veteran as Vice President of Regulatory Affairs

Jan 7, 2025, 4:05 PM EST - 1 year ago

Glucotrack to Present at TechBio Showcase™ 2025

Dec 6, 2024, 7:00 AM EST - 1 year ago

GlucoTrack Proxy statement: Proxy Filing

Dec 3, 2024, 8:30 AM EST - 1 year ago

GLUCOTRACK ANNOUNCES START OF ENROLLMENT FOR HUMAN CLINICAL STUDY OF CONTINUOUS BLOOD GLUCOSE MONITOR

RetiredOldGeezer Sep. 22 at 8:14 PM

$GCTK Taken again - that was slick.

1 · Reply

HMIC Sep. 22 at 8:13 PM

$GCTK Look for a Freaky Friday run.

0 · Reply

Tradr1205 Sep. 22 at 8:10 PM

$GCTK LESSSSGOOO!!!

0 · Reply

MrTicker Sep. 22 at 8:03 PM

$GCTK 720k float.. could be an interesting after hours to see where this closes

1 · Reply

MrTicker Sep. 22 at 8:02 PM

$GCTK on the move after hours.. + break on tap_

1 · Reply

RetiredOldGeezer Sep. 22 at 4:57 PM

$GCTK On my goodness - the hippie Hawaiians - where is your Lokahi - just a money grabber?

0 · Reply

OG80 Sep. 21 at 2:10 PM

$GCTK criminal

0 · Reply

focafoca99 Sep. 18 at 9:29 PM

$GCTK announced director Paul V. Goode's resignation over a potential conflict tied to its merger with Lokahi Therapeutics.

0 · Reply

pennysqueezepro Sep. 18 at 6:07 PM

$GCTK 👀

0 · Reply

OG80 Sep. 17 at 11:09 AM

$GCTK wheres the lawsuits?

0 · Reply

OG80 Sep. 16 at 6:04 PM

$GCTK

0 · Reply

OG80 Sep. 16 at 5:32 PM

$GCTK i believe it is.

0 · Reply

Skerk Sep. 16 at 4:16 PM

$GCTK where’d the company rep that was providing no valuable info go? Are they even allowed to do another r/s this year?

1 · Reply

VizTheWin Sep. 16 at 11:32 AM

$GCTK terrible people

0 · Reply

OG80 Sep. 16 at 10:58 AM

$GCTK

0 · Reply

Deerslayer1998 Sep. 16 at 7:44 AM

$GCTK what a joke. Like the old song says I fell into a burning ring of fire and it went down down down. CEO is a joke

1 · Reply

OG80 Sep. 14 at 1:41 PM

$GCTK worst investment ever

0 · Reply

OG80 Sep. 14 at 11:53 AM

$GCTK pos

0 · Reply

OG80 Sep. 14 at 11:31 AM

$GCTK being forced to liquidate because webull charges me for level 2 data and my account is 100% invested in stocks. telling me i have to sell more than 4x what i owe (11.50) in order to maintain my account. everything is a scam nowadays. cant even get data for free when they actively shill these companies to you. the fuck i have to pay 11.50 to see data? fuck everything and this stock.

0 · Reply

CallMeMyBeer Sep. 14 at 4:48 AM

$GCTK this is pathetic.

0 · Reply

TNNStockAnalysisNews Sep. 14 at 3:50 AM

Stocks under $4 to Watch Tomorrow (Sept 14, 2026): $ADBT Closed at $0.232, Down 24.82% in Extreme Volatility $GCTK Closed at $2.55, Down 21.05% Post-Reverse Split $OPTT Closed at $0.107, Down 33.44% Into Monday’s Split $NXXT Closed at $0.158, Down 18.32% Ahead of Monday’s Split $CRMT Closed at $1.90, Up 19.50% on a Stunning Earnings Beat https://truthsandnews.com/markets/stocks-under-4-to-watch-tomorrow-sept-14-2026

0 · Reply

Deerslayer1998 Sep. 14 at 3:32 AM

$GCTK omg this stock sucks. Wish I’d never tied my hard earned money in this joke. All kinds of promises and an fda that is probably willing to listen and crickets from management.

0 · Reply

Market Cap	1.62M
Revenue (ttm)	0.00
Net Income (ttm)	-19.39M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	-1.11

Volume	525,500
Avg Vol	942,160
Day's Range	N/A - N/A
Shares Out	706,000.00
Stochastic %K	4%
Beta	0.62
Analysts	Strong Buy
Price Target	N/A